Overview

The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
0
Participant gender:
All
Summary
Phase III, prospective, randomized, parallel, double blind, placebo-controlled study to determine whether Teriparatide can accelerate bone healing in unstable intertrochanteric fracture patients treated with Proximal Femoral Nail Antirotation (PFNA) assessed by radiographic and clinical outcomes.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
King Chulalongkorn Memorial Hospital
Treatments:
Calcium
Parathyroid Hormone
Teriparatide
Vitamin D
Vitamins
Criteria
Inclusion Criteria:

1. Male and female patient, age ≥ 50 years at the time of screening

2. Unstable intertrochanteric fracture (AO/OTA 31-A2 and 31-A3)

3. Treated by proximal femoral nail antirotation (PFNA)

Exclusion Criteria:

1. Known hypersentivity to teriparatide or any form of PTH or analogue

2. Metabolic bone disease other than primary osteoporosis (including Hyper Parathyroidism
and Paget's disease of bone)

3. Increased baseline risk of osteosarcoma (Paget's disease of the bone, previous primary
skeletal malignancy, or skeletal exposure to therapeutic irradiation)

4. History of malignant neoplasm in the 5 years prior to the study (with the exception of
superficial basal cell carcinoma or squamous cell carcinoma) and carcinoma in situ of
the uterine cervix treated less than 1 year prior to the study.

5. Pre-existing of hypercalcemia (total serum calcium >10.5 mg/dL or 2.6 mmol/L)

6. Abnormally elevated serum intact parathyroid hormone at screening (serum PTH > 70
pg/mL)

7. Severe vitamin D deficiency (25-hydroxyvitamin D < 12 ng/mL)

8. Unexplained elevations of alkaline phosphatase (ALP > 120 UL)

9. Severe renal impairment (CrCL < 30 mL/min)

10. Current treatment with digoxin and necessary to continue use during the study

11. Concurrent treatment with oral bisphosphonates, selective estrogen receptor modulator
(SERMs), calcitonin, estrogen (oral, transdermal, or injection), progestin, estrogen
analog, estrogen agonist, estrogen antagonist or tibolone, and active vitamin D3
analogs. (Previous treatment is allowed but must be discontinued at screening)

12. Previous treatment with strontium ranelate for any duration, intravenous
bisphophonates within 12 months prior to the screening date, and/or denosumab within 6
months prior to the screening.

13. Previous treatment with teriparatide, PTH or other PTH analogs, or prior participation
in any other clinical trial studying teriparatide, PTH or other PTH analogs